P Khwaja Abdul Hamied, the Iounder oI Cipla, was born on

October 31, 1898. The Iire oI nationalism was kindled in him

when he was 15 as he witnessed a wanton act oI colonial
highhandedness.
P In college, he Iound Chemistry Iascinating. He set sail Ior
Europe in 1924 and got admission in Berlin University as a
research student oI "The Technology oI Barium Compounds".
He earned his doctorate three years later.
P In October 1927, during the long voyage Irom Europe to
India, he drew up great plans Ior the Iuture. He wrote: "No
modern industry could have been possible without the help oI
such centres oI research work where men are engaged in
compelling nature to yield her secrets to the ruthless search oI
an investigating chemist."
P In 1935, he set up The Chemical, Industrial & Pharmaceutical
Laboratories, which came to be popularly known as Cipla. He
gave the company all his patent and proprietary Iormulas Ior
several drugs and medicines, without charging any royalty.
On August 17, 1935, Cipla was registered as a public limited
company with an authorised capital oI Rs 6 lakhs.
P uly 4, 1939 was a red-letter day Ior Cipla, when the Father
oI the Nation, Mahatma Gandhi, honoured the Iactory with a
visit. He was "delighted to visit this Indian enterprise", he
noted later. From the time Cipla came to the aid oI the nation
gasping Ior essential medicines during the Second World
War, the company has been among the leaders in the
pharmaceutical industry in India.
P
In 1946, Cipla's product Ior hypertension, $07534/ , was exported
to the American Roland Corporation, to the tune oI Rs 8 lakhs. Five
years later, the company entered into an agreement with a Swiss Iirm
Ior manuIacturing Ioromycene.
Dr YusuI Hamied, the Iounder's son, returned with a doctorate in
chemistry Irom Cambridge and joined Cipla as an oIIicer in charge
oI research and development in 1960.
In 1961, the Vikhroli Iactory started manuIacturing diosgenin. This
heralded the manuIacture oI several steroids and hormones derived
Irom diosgenin.
Shore ho|d|ng Fottern
8cnk cf New Ycrk
Shcre: in Ircn:iI
FrcmcIer:
MuIuc| Func: & UIl
8cnk, Fincncic| ln:I,
ln:urcnce Ccmpcny
Fcreign ln:IiIuIicnc| lnve:Icr:
FrivcIe ccrpcrcIe ccmpcnie:
lncicn FuL|ic
NFl:
P Subsidiary Detail About Cipla acquired Irom The Annual
Report-2009/2010
As per the exemption order no. 47/307/2010-CL-III dated 22
nd
April 2010, passed
by the Ministry oI Corporate AIIairs, Government oI India under section 212(8) oI
the Companies Act, 1956, the audited Iinancial statements oI the subsidiary
company viz. Cipla FZE have not been attached. The consolidated Iinancial
statements presented in the Annual Report include Iinancial inIormation oI the
subsidiary company. A statement under section 212(3), which contains inIormation
in terms oI the exemption order, is also attached. In terms oI the aIoresaid approval,
the annual accounts oI the subsidiary company and the related detailed inIormation
will be made available upon request. These documents will also be available Ior
inspection by any member at the registered oIIice oI the Company.
P In May 2010, the Company has set up a wholly-owned subsidiary, 'Cipla
Singapore Pte. Ltd., in Singapore to aid logistics and distribution oI the
Company`s export business. In May 2010, Cipla acquired 100 per cent
shareholding oI a company Ior Rs.51.38 crore. This company has a state-oI-the-art
Iormulations manuIacturing Iacility at Sikkim with capabilities to manuIacture
tablets, capsules, oral liquids, injections, dry syrup and ointments/creams. This,
along with the acquisition oI the undertaking oI the API Iacility in Kurkumbh
under the slump sale arrangement mentioned earlier, was done with an objective to
exercise control over operations oI these Iacilities. Entities controlled by relatives
oI the promoters were major shareholders in the two units.
P In April 2010, the Company commenced commercial production
oI pharmaceutical Iormulations at its Special Economic Zone (SEZ)
project, at Indore, Madhya Pradesh. This project includes Iacilities Ior
the manuIacture oI aerosols, respules, liquid orals, pre-Iilled syringes
(PFS), nasal sprays, large volume parenterals (LVP), eye drops, tablets
and capsules. The total investment Ior this project is about Rs.900 crore.
P The Company is investing about Rs.250 crore in a new R&D and
administration Iacility atVikhroli, Mumbai.
P Cipla is setting up API Iacilities at Bengaluru Ior anti-cancer
products. The Company is upgrading its API Iacilities at Patalganga to
scale-up production. The total investment Ior these two projects is
estimated to be about Rs.200 crore.
SuL:icicry FccI: cnc lnve:ImenI::
P In May 2010, Cipla acquired an undertaking Ior Rs.30.64 crore, by
way oI a slump sale arrangement. The undertaking has a
manuIacturing Iacility, approved by US FDA and WHO, Ior APlsand
intermediates. It is located at Kurkumbh (Pune district).
P The Company proposes to subscribe to the share capital oI two
biotechnology companies, located in India and Hong Kong, to obtain a
40 per cent and a 25 per cent share, respectively. The total investment
will be about USD 65 million, in a phased manner, Ior setting up
state-oI-the-art Iacilities Ior bio similar products in Goa and China.
P Company's SEZ project at Kerim,Goa continues to be suspended due
to the stop-work order issued by the State Government. The Company
had received a communication dated 11
th
uly 2008 Iro m the State
Government revoking its stop-work order, consequent to the Iiling oI a
petition by the developer oI the SEZ against the order. The petition is
currently pending beIore the Goa Bench oI Bombay High Court.
P Cipla Medpro South AIrica Limited (Cipla Medpro) is a
subsidiary oI Cipla based in South AIrica. The company is
engaged in the manuIacturing, marketing and supplying oI
products related to the therapy areas including cardiovascular,
respiratory, diabetes, oncology, psychiatry, antimalarials,
neuro-psychiatry, and HIV/AIDS. Its products are avilable in
the dosage Iorms including tablets, capsules, powders, liquids,
creams / ointments. Cipla Medpro operations includes Cipla
Medproa and Contract manuIacturing. It also oIIers contract
manuIacturing solutions to pharmaceutical companies and also
engaged in the supply and distribution oI pharmaceutical
products.
P %% 8|o-Fhormo t|es w|th C|p|o
kEb%EkS
P %okyo, December 11: cpcn Lic-venIure firm LII 8ic-Fhcrmc Cc. LIc. :cic cn
Mcnccy iI hcc Icppec lncicn crug mcker Cip|c LIc Ic he|p iI ceve|cp
ncnc:Iercic:, which hcve Ihe pcIenIic| Ic Le mcre effecIive cnc prccuce
fewer :ice effecI: Ihcn ccnvenIicnc| :Iercic IrecImenI:.
P LII 8ic-Fhcrmc, whc:e :Icck :hcI up necr|y 4 percenI cn Ihe new:, :cic IhcI
c: pcrI cf Ihe cec|, iI wcu|c cuI:curce Ihe prccucIicn cf ncnc:Iercic: Ic
Cip|c.
P Ihe ccmpcny hc: hcc gccc re:u|I: in cnimc|: wiIh ncnc:Iercic: cnc :cy: iI
hcpe: Ic Legin c|inicc| Iric|: wiIhin Iwc yecr:.
P Ncnc:Iercic: cre c crug ce|ivery :y:Iem in which :Iercic: cre in:erIec inIc c
pc|y|ccIic ccic pcrIic|e wiIh c wicIh cf cn|y 150 ncncmeIre:.
P Ihe u:e cf Ihe pcrIic|e, which i: ce|iverec Ly inIrcvencu: injecIicn, c||cw: fcr c
:|cw re|ec:e Iime :c IhcI Ihe crug ccn Le effecIive fcr up Ic c week, Ihe
ccmpcny :cic.
P Ncnc:Iercic: c|:c c||cw c IcrgeIec ce|ivery IhcI :hcu|c he|p recuce :ice
effecI:, which ccn Le :evere in ccnvenIicnc| :Iercic IrecImenI.
P SIercic: cre u:ec Ic IrecI c vcrieIy cf ci:ec:e: inc|ucing crIhriIi: cnc c||ergy-
re|cIec ci:ec:e:.
P LII 8ic-Fhcrmc :cic Ihere were mcny Lic-venIure firm: crcunc Ihe wcr|c
wcrking in ncncmecicine LuI iI Le|ievec iI wc: Ihe cn|y cne wcrking cn
ncnc:Iercic:, which cre much mcre cifficu|I Ic mcke Ihcn cIher mecicine:.
P LII 8ic-Fhcrmc :hcre:, |i:Iec cn Ihe McIher: :IcrI-up :ecIicn cf Ihe Ickyc
SIcck Exchcnge, were up 1. percenI cI 108,000 yen in cfIernccn Ircce.
P SUMM/FY:
P Freci:e infcrmcIicn cLcuI Ihe :hcre
hc|cing pcIIern cf ClFL/ i: cIIcchec wiIh
Ihe emci| :epcrcIe|y. Ihi: i: :c Leccu:e
Ihe ccc wc: uncL|e Ic Le cIIcchec Ic
Ihi: FFI.
P ln :|ice numLer 7, we ccn :ee IhcI Ihe
SuL:icicry ceIci|: cre ncI revec|ec cnc
Ihe :cme i: menIicnec in Ihe /nnuc|
FepcrI-200/10.